Literature DB >> 7709457

Relevance of pretransplant donor-specific T cell allorepertoire for human kidney graft survival.

G J Bouma1, E M van der Meer-Prins, F J van der Woude, J J van Rood, F H Claas.   

Abstract

In order to determine whether the donor-specific T cell allorepertoire evaluated in patients before transplantation can be predictive for kidney graft survival, a study has been set up in which the number and activation state of donor-specific T lymphocytes before transplantation were correlated to transplant survival time. Limiting dilution analysis assays were carried out to determine precursor frequencies of both T helper and cytotoxic T lymphocytes. The activation state of these cells was studied by evaluating the inhibitory capacity of cyclosporine on helper and cytotoxic T cells and/or a monoclonal antibody directed against CD8 on cytotoxic T cells. This study shows that neither a significant difference in the number nor activation state of donor-directed helper and cytotoxic T cells before transplantation could be detected when patients who acutely rejected their grafts were compared with patients who still had a well-functioning kidney graft after more than 10 years. Moreover, no significant differences in the donor-specific T cell repertoire were found when patients who had been subject to multiple rejection episodes were compared with patients who experienced few complications after transplantation. Therefore, we conclude that in individuals who have not been sensitized to HLA antigens of the donor, the donor-specific peripheral T cell allorepertoire prior to transplantation is not predictive of kidney graft survival.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7709457     DOI: 10.1097/00007890-199504150-00008

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  1 in total

1.  Human allograft acceptance is associated with immune regulation.

Authors:  A M VanBuskirk; W J Burlingham; E Jankowska-Gan; T Chin; S Kusaka; F Geissler; R P Pelletier; C G Orosz
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.